The mechanisms by which polyamines accelerate tumor spread

Journal of Experimental & Clinical Cancer Research

Kuniyasu Soda¹ 

[1] Department of Surgery and Cardiovascular Research Institute, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya, Saitama-city, Saitama (330-0834), Japan

关键词: LFA-1;    LAK;    spermidine;    spermine;    metastasis;    Polyamine;   

Others  :  827191
DOI  :  10.1186/1756-9966-30-95

 received in 2011-07-15, accepted in 2011-10-11,  发布年份 2011

【 摘 要 】

Increased polyamine concentrations in the blood and urine of cancer patients reflect the enhanced levels of polyamine synthesis in cancer tissues arising from increased activity of enzymes responsible for polyamine synthesis. In addition to their de novo polyamine synthesis, cells can take up polyamines from extracellular sources, such as cancer tissues, food, and intestinal microbiota. Because polyamines are indispensable for cell growth, increased polyamine availability enhances cell growth. However, the malignant potential of cancer is determined by its capability to invade to surrounding tissues and metastasize to distant organs. The mechanisms by which increased polyamine levels enhance the malignant potential of cancer cells and decrease anti-tumor immunity are reviewed. Cancer cells with a greater capability to synthesize polyamines are associated with increased production of proteinases, such as serine proteinase, matrix metalloproteinases, cathepsins, and plasminogen activator, which can degrade surrounding tissues. Although cancer tissues produce vascular growth factors, their deregulated growth induces hypoxia, which in turn enhances polyamine uptake by cancer cells to further augment cell migration and suppress CD44 expression. Increased polyamine uptake by immune cells also results in reduced cytokine production needed for anti-tumor activities and decreases expression of adhesion molecules involved in anti-tumor immunity, such as CD11a and CD56. Immune cells in an environment with increased polyamine levels lose anti-tumor immune functions, such as lymphokine activated killer activities. Recent investigations revealed that increased polyamine availability enhances the capability of cancer cells to invade and metastasize to new tissues while diminishing immune cells' anti-tumor immune functions.

【 授权许可】

   
2011 Soda; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Durie BG, Salmon SE, Russell DH: Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res 1977, 37:214-221.
• [2]Loser C, Folsch UR, Paprotny C, Creutzfeldt W: Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer. Cancer 1990, 65:958-966.
• [3]Chatel M, Darcel F, Quemener V, Hercouet H, Moulinoux JP: Red blood cell polyamines as biochemical markers of supratentorial malignant gliomas. Anticancer Res 1987, 7:33-38.
• [4]Kubota S, Okada M, Yoshimoto M, Murata N, Yamasaki Z, Wada T, Imahori K, Ohsawa N, Takaku F: Urinary polyamines as a tumor marker. Cancer Detect Prev 1985, 8:189-192.
• [5]Uehara N, Shirakawa S, Uchino H, Saeki Y: Elevated contents of spermidine and spermine in the erythrocytes of cancer patients. Cancer 1980, 45:108-111.
• [6]Cipolla B, Guille F, Moulinoux JP, Bansard JY, Roth S, Staerman F, Corbel L, Quemener V, Lobel B: Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. J Urol 1994, 151:629-633.
• [7]Weiss TS, Bernhardt G, Buschauer A, Thasler WE, Dolgner D, Zirngibl H, Jauch KW: Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int J Colorectal Dis 2002, 17:381-387.
• [8]Linsalata M, Caruso MG, Leo S, Guerra V, D'Attoma B, Di Leo A: Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res 2002, 22:2465-2469.
• [9]Bergeron C, Bansard JY, Le Moine P, Bouet F, Goasguen JE, Moulinoux JP, Le Gall E, Catros-Quemener V: Erythrocyte spermine levels: a prognostic parameter in childhood common acute lymphoblastic leukemia. Leukemia 1997, 11:31-36.
• [10]Russell DH: Clinical relevance of polyamines. Crit Rev Clin Lab Sci 1983, 18:261-311.
• [11]Hochman J, Katz A, Bachrach U: Polyamines and protein kinase II. Effect of polyamines on cyclic AMP--dependent protein kinase from rat liver. Life Sci 1978, 22:1481-1484.
• [12]Tabib A, Bachrach U: Activation of the proto-oncogene c-myc and c-fos by c-ras: involvement of polyamines. Biochem Biophys Res Commun 1994, 202:720-727.
• [13]Panagiotidis CA, Artandi S, Calame K, Silverstein SJ: Polyamines alter sequence-specific DNA-protein interactions. Nucleic Acids Res 1995, 23:1800-1809.
• [14]Childs AC, Mehta DJ, Gerner EW: Polyamine-dependent gene expression. Cell Mol Life Sci 2003, 60:1394-1406.
• [15]Seiler N: Polyamine oxidase, properties and functions. Prog Brain Res 1995, 106:333-344.
• [16]Casero RA, Pegg AE: Polyamine catabolism and disease. Biochem J 2009, 421:323-338.
• [17]Pegg AE: Mammalian polyamine metabolism and function. IUBMB Life 2009, 61:880-894.
• [18]Gerner EW, Meyskens FL Jr: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004, 4:781-792.
• [19]Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillen-Rodriguez JM, Gerner EW: APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 1999, 20:1709-1713.
• [20]Becciolini A, Porciani S, Lanini A, Balzi M, Cionini L, Bandettini L: Polyamine levels in healthy and tumor tissues of patients with colon adenocarcinoma. Dis Colon Rectum 1991, 34:167-173.
• [21]Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R: Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res 1999, 5:2035-2041.
• [22]Radford DM, Nakai H, Eddy RL, Haley LL, Byers MG, Henry WM, Lawrence DD, Porter CW, Shows TB: Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia. Cancer Res 1990, 50:6146-6153.
• [23]Kingsnorth AN, Lumsden AB, Wallace HM: Polyamines in colorectal cancer. Br J Surg 1984, 71:791-794.
• [24]LaMuraglia GM, Lacaine F, Malt RA: High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg 1986, 204:89-93.
• [25]Takenoshita S, Matsuzaki S, Nakano G, Kimura H, Hoshi H, Shoda H, Nakamura T: Selective elevation of the N1-acetylspermidine level in human colorectal adenocarcinomas. Cancer Res 1984, 44:845-847.
• [26]Moulinoux JP, Quemener V, Khan NA, Delcros JG, Havouis R: Spermidine uptake by erythrocytes from normal and Lewis lung carcinoma (3LL) grafted mice: I. In vitro study. Anticancer Res 1989, 9:1057-1062.
• [27]Uda K, Tsujikawa T, Fujiyama Y, Bamba T: Rapid absorption of luminal polyamines in a rat small intestine ex vivo model. J Gastroenterol Hepatol 2003, 18:554-559.
• [28]Bardocz S, Brown DS, Grant G, Pusztai A: Luminal and basolateral polyamine uptake by rat small intestine stimulated to grow by Phaseolus vulgaris lectin phytohaemagglutinin in vivo. Biochim Biophys Acta 1990, 1034:46-52.
• [29]Bardocz S, Grant G, Brown DS, Ralph A, Pusztai A: Polyamines in food--implications for growth and health. J Nutr Biochem 1993, 4:66-71.
• [30]Soda K, Kano Y, Sakuragi M, Takao K, Lefor A, Konishi F: Long-term oral polyamine intake increases blood polyamine concentrations. J Nutr Sci Vitaminol (Tokyo) 2009, 55:361-366.
• [31]Soda K, Dobashi Y, Kano Y, Tsujinaka S, Konishi F: Polyamine-rich food decreases age-associated pathology and mortality in aged mice. Exp Gerontol 2009, 44:727-732.
• [32]Brodal BP, Eliassen KA, Ronning H, Osmundsen H: Effects of dietary polyamines and clofibrate on metabolism of polyamines in the rat. J Nutr Biochem 1999, 10:700-708.
• [33]Sarhan S, Knodgen B, Seiler N: The gastrointestinal tract as polyamine source for tumor growth. Anticancer Res 1989, 9:215-223.
• [34]D'Agostino L, Pignata S, Daniele B, D'Adamo G, Ferraro C, Silvestro G, Tagliaferri P, Contegiacomo A, Gentile R, Tritto G, et al.: Polyamine uptake by human colon carcinoma cell line CaCo-2. Digestion 1990, 46(Suppl 2):352-359.
• [35]Feige JJ, Chambaz EM: Polyamine uptake by bovine adrenocortical cells. Biochim Biophys Acta 1985, 846:93-100.
• [36]Cooper KD, Shukla JB, Rennert OM: Polyamine compartmentalization in various human disease states. Clin Chim Acta 1978, 82:1-7.
• [37]Upp JR Jr, Saydjari R, Townsend CM Jr, Singh P, Barranco SC, Thompson JC: Polyamine levels and gastrin receptors in colon cancers. Ann Surg 1988, 207:662-669.
• [38]Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, Gerner EW: Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 1993, 2:369-374.
• [39]Osborne DL, Seidel ER: Gastrointestinal luminal polyamines: cellular accumulation and enterohepatic circulation. Am J Physiol 1990, 258:G576-584.
• [40]Kobayashi M, Xu YJ, Samejima K, Goda H, Niitsu M, Takahashi M, Hashimoto Y: Fate of orally administered 15N-labeled polyamines in rats bearing solid tumors. Biol Pharm Bull 2003, 26:285-288.
• [41]Soda K, Kano Y, Nakamura T, Kasono K, Kawakami M, Konishi F: Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte. J Immunol 2005, 175:237-245.
• [42]Kano Y, Soda K, Nakamura T, Saitoh M, Kawakami M, Konishi F: Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion. Cancer Immunol Immunother 2007, 56:771-781.
• [43]Klein S, Miret JJ, Algranati ID, de Lustig ES: Effect of alpha-difluoromethylornithine in lung metastases before and after surgery of primary adenocarcinoma tumors in mice. Biol Cell 1985, 53:33-36.
• [44]Herr HW, Kleinert EL, Conti PS, Burchenal JH, Whitmore WF Jr: Effects of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice. Cancer Res 1984, 44:4382-4385.
• [45]Luk GD, Abeloff MD, Griffin CA, Baylin SB: Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res 1983, 43:4239-4243.
• [46]Kingsnorth AN, McCann PP, Diekema KA, Ross JS, Malt RA: Effects of alpha-difluoromethylornithine on the growth of experimental Wilms' tumor and renal adenocarcinoma. Cancer Res 1983, 43:4031-4034.
• [47]Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, et al.: Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 49:71-77.
• [48]Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G: Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006, 176:500-504.
• [49]Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al.: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008, 1:32-38.
• [50]Quemener V, Moulinoux JP, Havouis R, Seiler N: Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Anticancer Res 1992, 12:1447-1453.
• [51]Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW: Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 2010, 139:797-805. 805 e791
• [52]Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, et al.: Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003, 9:981-990.
• [53]Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 2008, 107:33-40.
• [54]Kubota S, Ohsawa N, Takaku F: Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo. Int J Cancer 1987, 39:244-247.
• [55]Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D, Verderame MF: Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. Clin Exp Metastasis 2005, 22:255-263.
• [56]MacDonald NJ, Steeg PS: Molecular basis of tumour metastasis. Cancer Surv 1993, 16:175-199.
• [57]Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 1983, 49:636-649.
• [58]Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009, 174:1588-1593.
• [59]Pouyssegur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
• [60]Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
• [61]Harris AL: Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
• [62]Beavon IR: Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol Pathol 1999, 52:179-188.
• [63]Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR: Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer 1998, 77:1799-1805.
• [64]Tantini B, Fiumana E, Cetrullo S, Pignatti C, Bonavita F, Shantz LM, Giordano E, Muscari C, Flamigni F, Guarnieri C, et al.: Involvement of polyamines in apoptosis of cardiac myoblasts in a model of simulated ischemia. J Mol Cell Cardiol 2006, 40:775-782.
• [65]Aziz SM, Olson JW, Gillespie MN: Multiple polyamine transport pathways in cultured pulmonary artery smooth muscle cells: regulation by hypoxia. Am J Respir Cell Mol Biol 1994, 10:160-166.
• [66]Tsujinaka S, Soda K, Kano Y, Konishi F: Spermine accelerates hypoxia-initiated cancer cell migration. Int J Oncol 2011, 38:305-312.
• [67]De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998, 34:162-168.
• [68]Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS: Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 1996, 78:1461-1469.
• [69]Sunkara PS, Rosenberger AL: Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice. Cancer Res 1987, 47:933-935.
• [70]Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997, 15:535-541.
• [71]Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18:1135-1149.
• [72]Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
• [73]Dvorak HF, Weaver VM, Tlsty TD, Bergers G: Tumor microenvironment and progression. J Surg Oncol 2011, 103:468-474.
• [74]Kubota S, Kiyosawa H, Nomura Y, Yamada T, Seyama Y: Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst 1997, 89:567-571.
• [75]Ashida Y, Kido J, Kinoshita F, Nishino M, Shinkai K, Akedo H, Inoue H: Putrescine-dependent invasive capacity of rat ascites hepatoma cells. Cancer Res 1992, 52:5313-5316.
• [76]Wallon UM, Shassetz LR, Cress AE, Bowden GT, Gerner EW: Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Mol Carcinog 1994, 11:138-144.
• [77]Matters GL, Manni A, Bond JS: Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. Clin Exp Metastasis 2005, 22:331-339.
• [78]Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Andersson LC, Holtta E: Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res 1997, 57:3016-3025.
• [79]Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A, Suzuki F: Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res 1990, 50:4131-4138.
• [80]Hersh EM, Gschwind C, Morris DL, Murphy S: Deficient strongly adherent monocytes in the peripheral blood of cancer patients. Cancer Immunol Immunother 1982, 14:105-109.
• [81]Grosser N, Marti JH, Proctor JW, Thomson DM: Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell. Int J Cancer 1976, 18:39-47.
• [82]MacFarlane JK, Thomson DM, Phelan K, Shenouda G, Scanzano R: Predictive value of tube leukocyte adherence inhibition (LAI) assay for breast, colorectal, stomach and pancreatic cancer. Cancer 1982, 49:1185-1193.
• [83]Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG: Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 2000, 82:1009-1012.
• [84]Rampone B, Rampone A, Tirabasso S, Panariello S, Rampone N: Immunological variations in women suffering from ovarian cancer. Influence of radical surgical treatment. Minerva Ginecol 2001, 53:116-119.
• [85]Monson JR, Ramsden C, Guillou PJ: Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 1986, 73:483-486.
• [86]Wood NL, Kitces EN, Blaylock WK: Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Arch Dermatol 1990, 126:907-913.
• [87]Hermann GG, Petersen KR, Steven K, Zeuthen J: Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol 1990, 10:311-320.
• [88]Funk J, Schmitz G, Failing K, Burkhardt E: Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol Immunother 2005, 54:87-92.
• [89]Balch CM, Itoh K, Tilden AB: Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 1985, 98:151-157.
• [90]Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH: Inhibition of interleukin 2 production by factors released from tumor cells. J Immunol 1983, 131:2837-2842.
• [91]Taylor DD, Bender DP, Gercel-Taylor C, Stanson J, Whiteside TL: Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer 2001, 84:1624-1629.
• [92]Byrd WJ, Jacobs DM, Amoss MS: Synthetic polyamines added to cultures containing bovine sera reversibly inhibit in vitro parameters of immunity. Nature 1977, 267:621-623.
• [93]Chamaillard L, Catros-Quemener V, Delcros JG, Bansard JY, Havouis R, Desury D, Commeurec A, Genetet N, Moulinoux JP: Polyamine deprivation prevents the development of tumour-induced immune suppression. Br J Cancer 1997, 76:365-370.
• [94]Lotzova E, Savary CA, Totpal K, Schachner J, Lichtiger B, McCredie KB, Freireich EJ: Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia. Leuk Res 1991, 15:245-254.
• [95]Loser C, Folsch UR, Paprotny C, Creutzfeldt W: Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer. Pancreas 1990, 5:119-127.
• [96]Nishiguchi S, Tamori A, Koh N, Fujimoto S, Takeda T, Shiomi S, Oka H, Yano Y, Otani S, Kuroki T: Erythrocyte-binding polyamine as a tumor growth marker for human hepatocellular carcinoma. Hepatogastroenterology 2002, 49:504-507.
• [97]Nishioka K, Romsdahl MM, McMurtrey MJ: Serum polyamine alterations in surgical patients with colorectal carcinoma. J Surg Oncol 1977, 9:555-562.
• [98]Colombatto S, Fasulo L, Fulgosi B, Grillo MA: Transport and metabolism of polyamines in human lymphocytes. Int J Biochem 1990, 22:489-492.
• [99]Bardocz S, Grant G, Brown DS, Ewen SW, Nevison I, Pusztai A: Polyamine metabolism and uptake during Phaseolus vulgaris lectin, PHA-induced growth of rat small intestine. Digestion 1990, 46(Suppl 2):360-366.
• [100]Cohen LF, Lundgren DW, Farrell PM: Distribution of spermidine and spermine in blood from cystic fibrosis patients and control subjects. Blood 1976, 48:469-475.
• [101]Ellis TM, Fisher RI: Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol 1989, 142:2949-2954.
• [102]Weil-Hillman G, Fisch P, Prieve AF, Sosman JA, Hank JA, Sondel PM: Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res 1989, 49:3680-3688.
• [103]Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984, 225:1487-1489.
• [104]Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985, 161:1169-1188.
• [105]Soda K, Kano Y, Nakamura T, Kawakami M, Konishi F: Spermine and spermidine induce some of the immune suppression observed in cancer patients. Annals of Cancer Research and Therapy 2003, 11:243-253.
• [106]Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A, Sherry B, Tracey KJ: Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med 1997, 185:1759-1768.
• [107]Hasko G, Kuhel DG, Marton A, Nemeth ZH, Deitch EA, Szabo C: Spermine differentially regulates the production of interleukin-12 p40 and interleukin-10 and suppresses the release of the T helper 1 cytokine interferon-gamma. Shock 2000, 14:144-149.
• [108]Bowlin TL, McKown BJ, Sunkara PS: The effect of alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on mitogen-induced interleukin 2 production. Immunopharmacology 1987, 13:143-147.
• [109]Chamaillard L, Quemener V, Havouis R, Moulinoux JP: Polyamine deprivation stimulates natural killer cell activity in cancerous mice. Anticancer Res 1993, 13:1027-1033.
• [110]Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975, 72:3666-3670.
• [111]Wacholtz MC, Patel SS, Lipsky PE: Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med 1989, 170:431-448.
• [112]Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meazza R, Canevari S, Colnaghi MI, Moretta L: The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Int J Cancer 1994, 56:846-852.
• [113]Sarhan S, Weibel M, Seiler N: Effect of polyamine deprivation on the survival of intracranial glioblastoma bearing rats. Anticancer Res 1991, 11:987-992.
• [114]Seiler N, Sarhan S, Grauffel C, Jones R, Knodgen B, Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res 1990, 50:5077-5083.
• [115]Cipolla BG, Havouis R, Moulinoux JP: Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomed Pharmacother 2010, 64:363-368.
• [116]Page GG, Ben-Eliyahu S, Liebeskind JC: The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994, 8:241-250.
• [117]Pollock RE, Babcock GF, Romsdahl MM, Nishioka K: Surgical stress-mediated suppression of murine natural killer cell cytotoxicity. Cancer Res 1984, 44:3888-3891.
• [118]Hattori T, Hamai Y, Harada T, Ikeda H, Ikeda T: Enhancing effect of thoracotomy and/or laparotomy on the development of the lung metastases in rats after intravenous inoculation of tumor cells. Jpn J Surg 1977, 7:263-268.
• [119]Tsukamoto T, Kinoshita H, Hirohashi K, Kubo S, Otani S: Human erythrocyte polyamine levels after partial hepatectomy. Hepatogastroenterology 1997, 44:744-750.
• [120]Aziz SM, Gillespie MN, Crooks PA, Tofiq SF, Tsuboi CP, Olson JW, Gosland MP: The potential of a novel polyamine transport inhibitor in cancer chemotherapy. J Pharmacol Exp Ther 1996, 278:185-192.
• [121]Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O'Brien TG: Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer 2006, 118:2344-2349.